ScholarIQanswers from OpenAlex & ORCID
Henk van den Berg
ResearcherPublications, citations & collaboration network
Henk van den Berg is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Henk van den Berg have?
ScholarIQindexed works
Henk van den Berg has 474 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Henk van den Berg have?
ScholarIQcitation count
Henk van den Berg has 19,575 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Henk van den Berg?
ScholarIQh-index
Henk van den Berg has an h-index of 72 in OpenAlex.
What is the i10-index of Henk van den Berg?
ScholarIQi10-index
Henk van den Berg has an i10-index of 277 in OpenAlex.
What is the ORCID of Henk van den Berg?
ScholarIQorcid
The ORCID for Henk van den Berg is on the source record.
What is the OpenAlex record for Henk van den Berg?
ScholarIQopenalex
The OpenAlex for Henk van den Berg is on the source record.
What are the most-cited papers on Henk van den Berg?
ScholarIQmost cited works
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina, Sigbjørn Smeland, Stefan Bielack, Mark L. Bernstein, Gordana Jovic, Mark Krailo, Jane Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken Brown, Trude Butterfaß‐Bahloul, Gabriele Calaminus, Heike E. Daldrup‐Link, Mikael Eriksson, Mark C. Gebhardt, Hans Gelderblom, Joachim Gerß, Robert E. Goldsby, Allen M. Goorin, Richard Görlick, Holcombe E. Grier, Juliet Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S. Hawkins, K. Helmke, Pancras C.W. Hogendoorn, Michael S. Isakoff, Katherine A. Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Paul A. Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Pápai, R. Lor Randall, Peter Reichardt, Marleen Renard, Akmal Safwat, Cindy L. Schwartz, Michaël C.G. Stevens, Sandra J. Strauss, Lisa A. Teot, Mathias Werner, Matthew R. Sydes, Jeremy Whelan
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan, Neyssa Marina, Gordana Jovic, Jane Hook, Mark Krailo, Mark C. Gebhardt, Zsuzsanna Pápai, James S. Meyer, Helen Nadel, R. Lor Randall, Claudia Deffenbaugh, Rajaram Nagarajan, Bernadette Brennan, G. Douglas Letson, Lisa A. Teot, Allen M. Goorin, Daniel Baumhoer, Leo Kager, Mathias Werner, Ching C. Lau, Kirsten Sundby Hall, Hans Gelderblom, Paul A. Meyers, Richard Görlick, Reinhard Windhager, K. Helmke, Mikael Eriksson, Peter M. Hoogerbrugge, Paula J. Schomberg, Per‐Ulf Tunn, Thomas Kühne, Heribert Jürgens, Henk van den Berg, Tom Böhling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerß, Trude Butterfaß‐Bahloul, Carol D. Morris, Pancras C.W. Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R. Sydes, Mark L. Bernstein